参考文献：

1.中华医学会血液学分会. 骨髓增生异常综合征中国诊断与治疗指南（2019 年版）. 中华血液学杂志. 2019, 40(2):89-97

2.Henry DH,et al. Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study. Am J Hematol. 2022 Feb 1;97(2):174-184.

3.冯悦，等. 输血依赖型较低危组骨髓增生异常综合征的治疗进展. 肿瘤防治研究. 2021, 48(4): 409-413

4.Zeidan AM, et al. Blood Rev. 2019;34:1–15

5.Malcovati L, et al. Haematologica. 2011;96:1433–1440

6.Fenaux P, Platzbecker U, Mufti GJ et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med 2020; 382: 140–151.

7.Platzbecker U, et al. Lancet 2023 Jul;402:373–85

8.Guillermo GM, et al. ASH 2024. Oral presentation 350

9.Oliva E et al. HemaSphere 2024;8(S1):P774.

10.Fenaux P, Platzbecker U, Mufti GJ et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med 2020; 382: 140–151.

11.中国临床肿瘤学会（CSCO）. 恶性血液病诊疗指南2025版.

12.美国国立综合癌症网络（NCCN）. 骨髓增生异常综合征临床实践指南Version 2.2025

13.Mount Sinai. Myelodysplastic Syndrome. Available at: http://www.mountsinai.org/care/cancer/services/mds. Accessed March 2023.

14.Myelodysplastic Syndromes Foundation. What is MDS? Available at: http://www.cancer.org/cancer/myelodysplastic-syndrome/about/what-is mds.html. Accessed March 2023.

15.Johns Hopkins Medicine. Myelodysplastic Syndrome. Available at: http://www.hopkinsmedicine.org/kimmel_cancer_center/types_cancer/myelodys

plastic_syndrome.html. Accessed March 2023.

16.Rasel M, Mahboobi SK. Transfusion Iron Overload. PubMed. 2021. Available at: http://www.ncbi.nlm.nih.gov/books/NBK562146/. Accessed March 2023.

17.Triantafyllidis I, Ciobanu A, Stanca O, Lupu AR. Prognostic factors in myelodysplastic syndromes. Maedica (Bucur). 2012 Dec;7(4):295-302. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593279. Accessed March 2023.

18.Galanello R, Origa R. Beta thalassemia. Orphanet Journal of Rare Diseases. 2010;5(11). Available at: http://ojrd.biomedcentral.com/articles/10.1186/1750-

1172-5-11. Accessed March 2023.